Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
91 studies found for:    Narcolepsy
Show Display Options
Rank Status Study
1 Recruiting A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy
Condition: Narcolepsy
Intervention:
2 Completed A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy
Condition: Narcolepsy
Interventions: Drug: JNJ-17216498;   Drug: Modafinil
3 Completed
Has Results
Risk of Narcolepsy Associated With Administration of H1N1 Vaccine
Condition: Narcolepsy
Intervention: Biological: A/H1N1 vaccine
4 Recruiting Metabolism Characteristics in the Children With Narcolepsy
Condition: Narcolepsy
Intervention: Other: Sleep and metabolism assessment
5 Completed Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy
Condition: Narcolepsy
Intervention: Drug: Modafinil
6 Recruiting Xyrem and Brain Dopamine in Narcolepsy
Condition: Narcolepsy With Cataplexy
Intervention: Drug: Xyrem
7 Completed Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy
Condition: Narcolepsy
Intervention: Drug: Armodafinil
8 Terminated Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy
Condition: Narcolepsy
Intervention: Drug: GSK189254
9 Completed
Has Results
Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy
Condition: Narcolepsy
Interventions: Drug: Xyrem;   Drug: Xyrem Placebo;   Drug: Modafinil at established dose;   Drug: Modafinil (Placebo)
10 Completed Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.
Condition: Treatment of Excessive Daytime Sleepiness in Narcolepsy.
Interventions: Drug: BF2.649;   Drug: Vigil;   Drug: palcebo
11 Completed PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
Conditions: Narcolepsy;   Sleep Apnea, Obstructive
Intervention: Drug: Modafinil
12 Completed Body Weight Regulation in Patients With Narcolepsy
Condition: Narcolepsy
Intervention:
13 Completed
Has Results
A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy
Condition: Narcolepsy
Interventions: Drug: ADX-N05;   Drug: Placebo
14 Completed
Has Results
Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy
Condition: Narcolepsy
Intervention: Drug: Xyrem (sodium oxybate) oral solution
15 Completed
Has Results
Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy
Condition: Narcolepsy
Interventions: Drug: Armodafinil;   Drug: Placebo
16 Active, not recruiting "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"
Condition: Narcolepsy
Intervention: Drug: JZP-110
17 Completed
Has Results
A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy
Conditions: Excessive Daytime Sleepiness;   Narcolepsy
Interventions: Drug: Placebo;   Drug: PF-03654746
18 Active, not recruiting Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)
Conditions: Narcolepsy;   Cataplexy
Intervention: Drug: BF2.649
19 Recruiting Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy
Conditions: Narcolepsy;   Excessive Sleepiness
Interventions: Drug: JZP-110;   Drug: Placebo
20 Recruiting Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease
Conditions: Parkinson Disease;   Sleep Disorders
Intervention: Drug: Stalevo®

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.